PRODUCTS & INNOVATION
Sustainability isn't just a buzzword — it's an integral part of everything we do.
Aug 30 2018
At Abbott, our goal is not just to help people live their best lives through life-changing technology – it's also to make this important work sustainable for the future.
For us, sustainability is about applying the power of our business to drive positive economic, social and environmental impact – making sure that the work we do helps people live healthier and better, both today and for generations to come. For a comprehensive look at our economic, social and environmental progress and performance, check out our newly published 2017 Global Sustainability Report. But for a quick view of our sustainability work, look no further than our pioneering technologies.
Take the FreeStyle Libre® system, our groundbreaking continuous glucose monitor that delivers a glucose reading with just a wave of a hand. Most people don't think of a diabetes monitor when they think about sustainability – but at the intersection of technology and sustainability, you'll find the FreeStyle Libre system. Read on to learn more about the many ways our work has a sustainable impact, through the lens of a single product.
For the more than 400 million people living with diabetes globally1, monitoring glucose levels regularly is critically important – but also painful and inconvenient, requiring up to 10 fingersticks per day2.
With the FreeStyle Libre system, we've eliminated the need for fingersticks3, a major barrier to keeping close control of glucose levels. FreeStyle Libre's sensor is painlessly applied to the skin on the back of the upper arm. It's thin and unobtrusive, but it's a technological powerhouse, checking glucose every minute and storing that information for up to eight hours.
So when the user checks their glucose level, it also tells them if they are trending up or down, giving them valuable information that can help them make treatment decisions. Managing diabetes has never been simpler.
"The FreeStyle Libre system empowers people with diabetes to take control of their lives, make informed health decisions and live life fully without the burden of fingersticks," said Jared Watkin, senior vice president of Abbott's diabetes care business. "The FreeStyle Libre system is living up to its full potential of truly being a life-changing technology for the millions of people living with diabetes globally."
One of the key sites for producing the FreeStyle Libre system in Witney, England, is also one of Abbott's 32 sites that send zero waste to landfills. All waste, from factory waste to cafeteria waste, is recycled, reused, composted or responsibly incinerated, and much of that energy is recaptured for future use. The Witney site also contributes to Abbott's broader 2020 global goals to reduce carbon emissions by 40 percent and waste by 50 percent (both based on 2010 and adjusted for sales). To date, Abbott has reduced emissions by 35 percent and waste by 41 percent since 2010.
We also work with suppliers that share our dedication to sustainability – for example, our suppliers have high-speed, automated production lines to produce components at a scale and cost to help keep the product affordable. And we have chosen suppliers close to our Witney site to reduce the risk of delivery disruptions and to minimize transport cost and environmental impact.
Reduced environmental impact for consumers
Similar to single-use straws, a diabetic test strip is small and may not seem like much to throw away. But considering that millions of people with diabetes need to use test strips multiple times per day, the waste quickly adds up. Fortunately, by eliminating fingersticks3, the FreeStyle Libre system removes the need to use tests strips routinely – allowing people with diabetes currently using the system to avoid throwing out an estimated 1.8 billion test strips each year.4
In addition, Abbott also recently gained approval in the U.S. for the FreeStyle Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor for two weeks, vs. 10 days that were approved in the past. This means people will need to replace their sensors less often – using up to 10 fewer sensors per year5.
Access and affordability
From the beginning, we have worked to provide broad access to the FreeStyle Libre system in countries around the world. This includes a global pricing structure that keeps the product low-priced, with costs averaging the equivalent of just two cups of coffee per day. Beyond the price of the system, the FreeStyle Libre system also saves users from having to pay for test strips that are typically used for routine blood glucose self-monitoring3. Abbott recently presented data that showed FreeStyle Libre users saw savings of more than $120 a month by eliminating the cost of test strips6.
We also work with governments around the world to qualify the FreeStyle Libre system for government reimbursement, making the device more accessible for people who could most benefit.
All of this work is translating into rapid access for people with diabetes: the FreeStyle Libre system is now available in more than 43 countries and is partially or fully reimbursed in 30 of them – with 800,000 people currently using the system7.
Reduced cost burden on society
It's estimated that approximately 6-17 percent of healthcare spending is allocated for diabetes in countries around the world8. The FreeStyle Libre system is designed to reduce costs, not only by making the device affordable to individuals but by reducing the cost of diabetes for local healthcare systems9. The FreeStyle Libre system is supported by both clinical data10, 11, and real-world evidence12 that show that people who scan more frequently spend less time in hypoglycemia (low-glucose levels) or hyperglycemia (high-glucose levels) while having improved average glucose levels, demonstrating improved glucose control overall.
Better glucose control means healthier people, which can result in hospital cost savings and the reduction of long-term complications related to diabetes13, potentially lessening the impact of one of the world's leading non-communicable diseases (NCDs). For example, we've shown in two recent randomized control trials that the use of the FreeStyle Libre system has led to a reduction in hospitalizations, ER visits and ambulance use14.
Empowering the diabetes community
When you're living with a chronic condition like diabetes, it's always good to know someone is in your corner, which is why we support the diabetes community in countries around the world.
One example: in Chile, Abbott partnered with the Fundación Diabetes Juvenil de Chile (FDJ), a local nonprofit dedicated to supporting young people with diabetes.
Abbott trains FDJ employees, offers discounted products, helps expand clinics, and developed an online pharmacy that makes products like the FreeStyle Libre system available to people throughout the country. All with the goal of providing people with the tools and information to successfully manage their diabetes.
Next step: connected care
The FreeStyle Libre system is designed to provide users with the information they need to make smart treatment decisions. The next step is moving from handheld devices like FreeStyle Libre readers to connected consumer electronic devices like smartphones and smart watches. This shift is already underway in Europe, where Abbott has launched the FreeStyle LibreLink mobile app15. This app allows users to access glucose data directly from their compatible smartphones16, eliminating the need for a separate reader17.
"There are several fundamental shifts that are transforming glucose monitoring and diabetes management, including moving from test strips to sensor-based technologies, moving from proprietary handheld devices to connected devices like mobile phones, and moving information to cloud-based solutions to support clinical decisions," said Joel Goldsmith, senior director of digital platforms for Abbott's diabetes care business. "These shifts will enable advancements in machine learning and artificial intelligence to make a meaningful impact on how diabetes is managed and treated in the future."
For more examples of how Abbott products, people and broader business are advancing sustainability around the world, check out our 2017 Global Sustainability Report.
Indications and Important Safety Information
FreeStyle Libre and FreeStyle Libre 14 day Flash Glucose Monitoring systems are continuous glucose monitoring (CGM) devices indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The systems are intended for single patient use and require a prescription.
CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.
WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The systems do not have alarms unless the sensor is scanned, and the systems contain small parts that may be dangerous if swallowed. The systems are not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes.
Review all product information before use or contact Abbott Toll Free (855-632-8658) (or visit www.freestylelibre.us) for detailed indications for use and safety information. For full indications for use and safety information, see more here.
1. World Health Organization. Diabetes Fact Sheet. Available http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed March 19, 2018.
2. American Diabetes Association Standards of medical care in diabetes 2014. Diabetes Care January 2014, v37 suppl1 s21-22
3. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose
4. Number based on following calculation: 800,000 users x 6 strips per day x 365 days = 1.752 billion.
5. Number based on following calculation: 10-day sensor = 37 sensors/year; 14-day sensor = 27 sensors/year. 37 – 27 = 10.
6. Hellmund, Richard. Cost Calculation and Adherence to ADA Recommendations based on a Flash Continuous Glucose Monitoring System. Presented at the American Diabetes Association 78th Scientific Sessions. https://plan.core-apps.com/tristar_ada18/abstract/5188446740e191fd289345d56a78cdc8
7. Data on file: Abbott Diabetes Care
8. IDF Diabetes Atlas, 8th Edition, pg. 54.
9. Hellmund R. Cost calculation and adherence to ADA recommendations based on a flash continuous glucose monitoring system for people with T1DM or T2DM using MDI therapy [Abstract]. Diabetes 2018;67 (Suppl 1):69-LB. https://doi.org/10.2337/db18-69-LB
10. Haak, Thomas, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Therapy 8.1 (2017): 55-73
11. Bolinder, Jan, et al. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet 388.10057 (2016): 2254-2263
12. Pryor, Heather et al. Real-world Patterns of Daytime and Nocturnal Hypoglycemia during Flash Continuous Glucose Monitoring. Presented at the American Diabetes Association 78th Scientific Sessions. https://plan.core-apps.com/tristar_ada18/abstract/5188446740e191fd289345d56a7d4359
13. Hellmund R, Weitgasser R, Blissett D. Cost calculation for a flash glucose monitoring system for UK adults with type 1 diabetes mellitus receiving intensive insulin treatment. Diabetes Res Clin Pract 2018. https://www.ncbi.nlm.nih.gov/pubmed/29410149. 10.1016/j.diabres.2018.01.028
14. Budget impact analysis of a flash glucose monitoring system for people with type 2 diabetes who are using intensive insulin [Poster]. Presented at the International Society for Pharmacoeconomics and Outcomes Research 19th Annual European Congress, 29 October–2 November 2016, Vienna, Austria.
15. Pending FDA approval. Not available for sale in the United States.
16. The FreeStyle LibreLink app is designed to be compatible with NFC enabled phones running Android OS 5.0 or higher and with iPhone 7 and later running OS 11 and later.
17. The FreeStyle LibreLink app and the FreeStyle Libre reader are designed to have similar but not identical features. A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the sensor or when symptoms do not match the sensor readings.
For Diabetes Testing, the Future is WOW
Revolutionizing CGM with FreeStyle Libre
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.